Description: Bio-Techne (TECH) stock saw a quick boost as investors responded to reports that the Trump administration is considering a two-year extension of Affordable Care Act subsidies. This development is easing some regulatory uncertainty for the healthcare sector. See our latest analysis for Bio-Techne. Momentum in Bio-Techne’s share price has picked up recently, with a strong 4.84% gain over the last week and an 18.09% rise in the past 90 days. This may be due to easing regulatory worries following...

Description: Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:

Description: A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.

Description: From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 14.5% over the past six months while the S&P 500 was up 11.5%.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Bio-Techne recently announced a licensing agreement with Monod Bio, granting it exclusive commercial rights to a subset of AI-designed NovoBody™ Duo molecules for use in research and next-generation diagnostics. This collaboration expands Bio-Techne's recombinant protein and diagnostics portfolio and strengthens its position at the forefront of AI-powered precision medicine innovation. We'll explore how gaining exclusive access to cutting-edge AI-designed protein technologies could influence...

Description: Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.

Description: ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an environment of shifting monetary policy, stabilizing earnings, and improved sentiment, midcaps experienced growth in the third quarter. The Federal Reserve’s decision to cut rates helped small and mid-cap stocks […]

Description: Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Q3 revenues increased by 18% to $27.4 millionAdjusted EBITDA profitability of $1.0 million for Q3Acquisition of ExoDx business from Bio-Techne CorporationConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for th

Description: The most recent earnings report from Bio-Techne Corporation ( NASDAQ:TECH ) was disappointing for shareholders. Despite...

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Targa Resources reported a solid third-quarter beat driven by volume growth in the gathering & processing segment and also plans to come in at the high end of the previous fiscal-2025 adjusted Ebitda guidance. It also bought back about $156 million of stock during the quarter and announced a 25% dividend increase for 2026; we thus expect investors to view this update positively. Bio-Techne reported below-expected financial results for its first-quarter 2026 (September), including revenue of $286.6 million, down 1% year over year, and flat adjusted earnings of $0.42 versus $0.42 for first-quarter 2025.

Description: Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:

Description: Bio-Techne (TECH) reported net profit margins of 6%, dropping from 14.5% the previous year, with earnings declining at an average annual rate of 6.8% over the last five years. The latest results were hit by a sizable one-off loss of $164.1 million, complicating year-over-year comparisons and weighing on recent profitability. Despite this, forecasts point to annual earnings growth of 12.5% and revenue growth of 8.1%, both trailing the broader US market. Shares trade at $59.94, well below an...

Description: Bio-Techne Corp (TECH) demonstrates resilience with margin improvements and innovation, despite facing revenue headwinds and a challenging biotech funding environment.

Description: Bio-Techne's Q1 earnings meet expectations, but revenues slip 1%, sending shares lower despite stronger margins.

Description: While the top- and bottom-line numbers for Techne (TECH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Techne (TECH) delivered earnings and revenue surprises of 0.00% and -0.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Life sciences company Bio-Techne (NASDAQ:TECH) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was in line with analysts’ consensus estimates.

Description: Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Description: Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2025.

Description: Bio-Techne (TECH) is catching eyes ahead of its upcoming quarterly earnings, with recent buzz fueled by strong clinical data at SITC 2025 and the debut of new spatial biology tools. These developments highlight the company’s expanding footprint in immuno-oncology research. See our latest analysis for Bio-Techne. Bio-Techne’s share price has seen pockets of momentum lately, jumping on the back of positive clinical data and new spatial biology products. Some gains have faded as investors absorb...

Description: Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, and Nucleai, a leader in AI-powered multimodal spatial biology for precision medicine, today announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.

Description: ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sonoma Biotherapeutics has been awarded a $300,000 G-Rex® Grant. SonomaBio's G-Rex® Grant will enable expeditious development of a G-Rex® based manufacturing process to produce gene-modified regulatory T cell (Treg) therapies for clinical investigation of SonomaBio products in development for various autoimmune related disorders.

Description: Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment firm raised its price target on Bio-Techne to $62 from $53. The stock's rise also occurred as the broader market showed strength. Stocks rose after solid earnings reports from major tech companies like Apple and Amazon beat expectations, which seemed to spark a rally in the sector. Bio-Techne's move f

Description: Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Bio-Techne Corporation recently launched the ProximityScope™ assay, an innovative spatial biology solution designed for integration with Leica Biosystems' BOND RX platform, enabling subcellular visualization of protein-protein interactions and multiomic analyses. This technology offers researchers unprecedented accuracy and insight by enabling simultaneous detection of RNA and proteins in tissue sections, addressing critical gaps left by traditional protein interaction assays. We'll examine...

Description: Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of the ProximityScope™ assay, a groundbreaking spatial solution developed for seamless integration with the BOND RX staining platform from Leica Biosystems. This powerful combination enables researchers to visualize functional protein-protein interactions on fixed tissue with subcellular resolution – bringing Leica's automation excellence from Leica Biosys

Description: The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Description: TECH's Q1 results could reflect steady Protein Sciences growth but pressure in Spatial Biology amid NIH and biotech funding uncertainty.

Description: ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, announced four G-Rex Grants have been awarded to faculty members at Children's National Hospital. The funding, totaling $375,000, will support the optimization and translation of various cell and gene therapy initiatives into the clinic.

Description: If you’re weighing your next move with Bio-Techne stock, you’re certainly not alone. After a bumpy stretch over the past year, the stock is making its way back on investors’ watchlists, and for good reason. In just the last month, Bio-Techne shares have climbed an impressive 20.1%, which suggests that something is shifting in how the market views this mid-cap life sciences company. Although the year-to-date return remains in negative territory at -13.5%, that recent surge hints at fresh...